Partial regression in thin primary cutaneous malignant melanomas clinical stage I. A study of 486 cases
- PMID: 3936263
- DOI: 10.1007/BF00707986
Partial regression in thin primary cutaneous malignant melanomas clinical stage I. A study of 486 cases
Abstract
486 patients with primary cutaneous malignant melanoma clinical stage I were examined in order to evaluate the prognostic importance of partial regression in thin lesions. All the melanomas measured 1 mm or less in maximal thickness. The study showed that past regression with fibrotic scar tissue adversely affected survival in patients with thin melanomas. The 10 year survival was 95% for patients without regression in contrast to 79% for patients with past regression. It was, furthermore, demonstrated that active regression without fibrotic scar tissue did not influence survival significantly. The wider and the thicker the fibrotic area, the poorer the survival. Although the prognostic importance of this finding was not statistically significant, we suggest that the horizontal width of the fibrotic area in particular may be a valuable prognostic guide in thin melanomas with past regression.
Similar articles
-
Regression in thin malignant melanoma. Microscopic diagnosis and prognostic importance.Arch Dermatol. 1985 Sep;121(9):1127-31. Arch Dermatol. 1985. PMID: 4037837
-
Thin malignant melanomas with regression and metastases.Arch Dermatol. 1987 Oct;123(10):1326-30. Arch Dermatol. 1987. PMID: 3662564
-
Regression in malignant melanoma. A histologic feature without independent prognostic significance.Cancer. 1985 Nov 1;56(9):2287-91. doi: 10.1002/1097-0142(19851101)56:9<2287::aid-cncr2820560924>3.0.co;2-y. Cancer. 1985. PMID: 4052972
-
Thin melanomas.Clin Lab Med. 2000 Dec;20(4):713-29. Clin Lab Med. 2000. PMID: 11221511 Review.
-
The nature of melanoma. A critical review.J Cutan Pathol. 1982 Apr;9(2):61-81. doi: 10.1111/j.1600-0560.1982.tb01044.x. J Cutan Pathol. 1982. PMID: 7047599 Review.
Cited by
-
Outcome of sentinel lymph node biopsy and prognostic implications of regression in thin malignant melanoma.Melanoma Res. 2012 Aug;22(4):302-9. doi: 10.1097/CMR.0b013e328353e673. Melanoma Res. 2012. PMID: 22610274 Free PMC article.
-
Regressing thin cutaneous malignant melanomas (< or = 1.0 mm) are associated with angiogenesis.Am J Pathol. 1993 Jul;143(1):99-104. Am J Pathol. 1993. PMID: 7686347 Free PMC article. Review.
-
Lethal "thin" malignant melanoma. Identifying patients at risk.Ann Surg. 1988 Aug;208(2):150-61. doi: 10.1097/00000658-198808000-00004. Ann Surg. 1988. PMID: 3401060 Free PMC article.
-
Bcl-2 expression in metastatic malignant melanoma. Importance for the therapeutic efficacy of biochemotherapy.Cancer Immunol Immunother. 2003 Apr;52(4):249-54. doi: 10.1007/s00262-003-0373-z. Epub 2003 Mar 4. Cancer Immunol Immunother. 2003. PMID: 12669250 Free PMC article. Clinical Trial.
-
Significance of Primary Melanoma Regression on Local Infiltrate and Outcome.Dermatol Pract Concept. 2022 Jan 1;12(1):e2022034. doi: 10.5826/dpc.1201a34. eCollection 2022 Feb. Dermatol Pract Concept. 2022. PMID: 35223178 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous